Third Harmonic Bio, Inc. (THRD)
(Real Time Quote from BATS)
$12.78 USD
-0.26 (-1.99%)
Updated Oct 2, 2024 03:00 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
THRD 12.78 -0.26(-1.99%)
Will THRD be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for THRD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for THRD
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
THRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Other News for THRD
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
Third Harmonic Bio to Participate in Upcoming Investor Conferences
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
THRD Stock Earnings: Third Harmonic Bio Beats EPS for Q2 2024
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)